Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals has announced a revision to the proposed increase in share reserve for their Equity Incentive Plan, reducing the number from 11,375,000 to 8,500,000 shares, ahead of their Annual General Meeting on June 14, 2024. This change brings the total increase to 32,315,115 shares, or 22.7% of the outstanding shares as of April 2024. This update comes as the company continues to focus on delivering treatments for autoimmune diseases, including their FDA-approved oral therapy for lupus nephritis.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
